Moracizine

Moracizine

File:Moricizin.svg
Systematic (IUPAC) name
ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate
Clinical data
Trade names	Ethmozine
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a601214
Pregnancy category	B (U.S.)
Pharmacokinetic data
Bioavailability	34–38%
Protein binding	95%
Biological half-life	3–4 hours (healthy volunteers), 6–13 hours (cardiac disease)
Identifiers
CAS Number	31883-05-3 Y
ATC code	C01BG01 (WHO)
PubChem	CID: 34633
IUPHAR/BPS	7244
DrugBank	DB00680 N
ChemSpider	31872 Y
UNII	2GT1D0TMX1 Y
KEGG	D05077 Y
ChEBI	CHEBI:6997 Y
ChEMBL	CHEMBL1075 Y
Chemical data
Formula	C22H25N3O4S
Molecular mass	427.518 g/mol
SMILES O=C(OCC)Nc2cc1N(c3c(Sc1cc2)cccc3)C(=O)CCN4CCOCC4
InChI InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27) Y Key:FUBVWMNBEHXPSU-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Moracizine (INN) or moricizine (USAN) (trade name Ethmozine) is an antiarrhythmic of class IC. It was used for the prophylaxis and treatment of serious and life-threatening ventricular arrhythmias, but was withdrawn in 2007 for commercial reasons.

Pharmacology

Moracizine, a phenothiazine derivative, undergoes extensive first-pass metabolism and is also extensively metabolized after it has entered the circulation. It may have pharmacologically active metabolites. A clinical study has shown that moracizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations. Compared with disopyramide and quinidine, moracizine was equally or more effective in suppressing premature ventricular contractions, couplets, and nonsustained ventricular tachycardia.

In the Cardiac Arrhythmia Suppression Trial (CAST), a large study testing the influence of antiarrhythmics on mortality, showed a non-significant increase of mortality from 5.4 to 7.2% under moracizine. This is in line with other class IC antiarrhythmics.